A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age

The Breast ◽  
2018 ◽  
Vol 41 ◽  
pp. S12
Author(s):  
Rinat Yerushalmi ◽  
Wolfgang Eiermann ◽  
Hope Rugo ◽  
Johannes Ettl ◽  
Sara A. Hurvitz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Brca Mutation ◽  
Parp Inhibitor ◽  
Advanced Breast ◽  
Phase 3 ◽  
Germline Brca Mutation ◽  
Choice Of Therapy

scholarly journals A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)

2015 ◽  
Vol 26 ◽  
pp. ii16 ◽  
Author(s):  
H. Roche ◽  
J. Blum ◽  
W. Eiermann ◽  
Y.-H. Im ◽  
M. Martin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Brca Mutation ◽  
Parp Inhibitor ◽  
Advanced Breast ◽  
Phase 3

scholarly journals Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 ◽  
Vol 379 (8) ◽  
pp. 753-763 ◽  
Author(s):  
Jennifer K. Litton ◽  
Hope S. Rugo ◽  
Johannes Ettl ◽  
Sara A. Hurvitz ◽  
Anthony Gonçalves ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Brca Mutation ◽  
Advanced Breast ◽  
Germline Brca Mutation
Sign in / Sign up

Export Citation Format

Share Document